Stay updated on CAB-AXL-ADC Study in NSCLC Clinical Trial
Sign up to get notified when there's something new on the CAB-AXL-ADC Study in NSCLC Clinical Trial page.

Latest updates to the CAB-AXL-ADC Study in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe study record describes a completed Phase 2 trial evaluating CAB-AXL-ADC alone and with a PD-1 inhibitor in adults with metastatic non-small-cell lung cancer. It provides the trial’s eligibility criteria, treatment arms, outcome measures, and participating locations.SummaryDifference71%

- Check11 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoChange DetectedA sitewide notice was added above the page, announcing an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check25 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1; the page otherwise remains a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now shows a 403 Forbidden message in place of the study record content, indicating the page failed to load; the layout shows only the header, a 403 message, and the footer.SummaryDifference18%

Stay in the know with updates to CAB-AXL-ADC Study in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAB-AXL-ADC Study in NSCLC Clinical Trial page.